Kairos Pharma, Ltd.

Stock market listings were back on the upswing last quarter, with the eight biotechs floating on Western exchanges raising a total of $1.1bn. In fact, there seems to have been a bit of a rush: three c

BioAge Labs, Inc. switched the development focus for its lead drug candidate, the small molecule apelin receptor (APJ) agonist azelaprag, from age-related muscle loss to prevention of muscle loss in

Biopharmaceutical companies celebrated recent positive data readouts with a slew of significant follow-on public offerings (FOPOs), including Nuvalent, Inc. , which grossed $500m on 16 September from